scispace - formally typeset
A

Aernout M. Beek

Researcher at VU University Medical Center

Publications -  112
Citations -  4782

Aernout M. Beek is an academic researcher from VU University Medical Center. The author has contributed to research in topics: Myocardial infarction & Magnetic resonance imaging. The author has an hindex of 38, co-authored 111 publications receiving 4472 citations. Previous affiliations of Aernout M. Beek include Indian Council of Agricultural Research & VU University Amsterdam.

Papers
More filters
Journal ArticleDOI

Standardizing the Definition of Hyperenhancement in the Quantitative Assessment of Infarct Size and Myocardial Viability Using Delayed Contrast-Enhanced CMR

TL;DR: Analyzing ceCMR with a standardized definition of hyperenhancement related to the signal of remote, nonenhanced myocardium may result in considerable overestimation of infarct size at the usual cut-off of 2 SD.
Journal ArticleDOI

Functional recovery after acute myocardial infarction: comparison between angiography, electrocardiography, and cardiovascular magnetic resonance measures of microvascular injury.

TL;DR: In patients after revascularized AMI, late MVO proved a more powerful predictor of global and regional functional recovery than all of the other characteristics, including transmural extent of infarction.
Journal ArticleDOI

Effect of endocardial trabeculae on left ventricular measurements and measurement reproducibility at cardiovascular MR imaging.

TL;DR: Differences in interobserver ED LV volume and LV mass and interexamination LV mass were statistically significant and favoring the inclusion of trabeculae in the LV cavity volume, favoring this tracing algorithm for clinical use.
Journal ArticleDOI

Myocardial viability in chronic ischemic heart disease: Comparison of contrast-enhanced magnetic resonance imaging with 18F-fluorodeoxyglucose positron emission tomography

TL;DR: Comparison of contrast-enhanced magnetic resonance imaging with nuclear metabolic imaging allows assessment of myocardial viability with a high accuracy, compared with FDG-PET, in patients with chronic ischemic heart disease and LV dysfunction.